Breast Cancer, Food And Drug Administration | featured news

FDA approves new targeted breast cancer drug

Roche

The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumor cells while sparing healthy ones. The drug Kadcyla (kad-SY'-luh) from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a double-shot of anti-tumor poison.

 

FDA questions safety of experimental diabetes drug

Federal health regulators have concerns about bladder and breast cancer seen in patients taking an experimental diabetes pill from Bristol-Myers ...

 

FDA to hear appeal on breast cancer drug Avastin

The best-selling cancer drug in the world comes under federal scrutiny as drugmaker Roche makes a last-ditch effort to keep Avastin approved ...

 

Subscribe to this RSS topic: Syndicate content